$16.89
-0.34(-1.95%)
Mkt Cap $312M
$16.90
$35.43
52-Week Range
At a Glance
AI-generatedRevenue breakdown: Direct Selling (99.7%), All Other (0.3%).
8-K
USANA Health Sciences, Inc. announced Q4 and FY 2025 financial results with net sales of $226.2 million and $925.3 million, respectively, alongside a Q4 GAAP net loss of $1.8 million due to $7.0 million impairment and $6.5 million cost realignment charges, and provided FY 2026 guidance for net sales of $925 million to $1.0 billion. The filing incorporates Exhibits 99.1 and 99.2 detailing results and outlook.$312M
Market Cap
$933M
Revenue
$11M
Net Income
Employees1,700
Fundamentals
How The Business Makes Money
Revenue by Segment
Direct Selling99.7%($3.1B)
All Other0.3%($9M)
Revenue by Geography
Asia Pacific32.8%($2.5B)
Greater China20.2%($1.5B)
CN18.1%($1.4B)
Southeast Asia Pacific8.2%($624M)
Americas And Europe7.9%($601M)
North Asia4.5%($340M)
US4.3%($331M)
KR4.1%($312M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000896264
ISINUS90328M1071
CUSIP90328M107
Phone801 954 7100
Address3838 West Parkway Boulevard, Salt Lake City, UT, 84120, US
SEC EDGAR